Click here for BeneFIX® (nonacog alfa) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
of responses were rated as excellent or effective (n=47)1,*
of responses were rated as excellent† (n=42), indicating that spontaneous musculoskeletal bleeding was prevented2
of patients under 6 years old experienced no spontaneous bleeding episodes whilst on prophylaxis (n=22)4
The response to secondary prophylaxis was assessed once every 3 months by the investigator using a 3-point scale: excellent (no spontaneous bleeding of any kind, no change in dosing regimen necessary); effective (no spontaneous musculoskeletal bleeding, no change in dosing regimen necessary); or inadequate (inadequate prevention of bleeding requiring a change in dosing regimen).1
†Rated by the investigator at 3-month intervals on a 3-point scale: excellent (prophylaxis treatment completely prevented spontaneous musculoskeletal bleeding, no change in dosing regimen necessary); effective (adequately prevented spontaneous musculoskeletal bleeding episodes as demonstrated by a lower than expected incidence of spontaneous musculoskeletal bleeding episodes); or inadequate (inadequate prevention of bleeding requiring a change in dosing regimen).2
of 1,796 bleeding episodes were resolved with only 1 infusion (n=55)1
of 997 bleeding episodes were resolved with only 1 infusion (n=54)2
of responses were rated excellent or good‡ (n=28)3,§
‡ Haemostasis was rated as excellent or good in 34 out of 35 of the operative procedures. Response ratings are defined as follows: excellent if the response was as satisfactory, with as much and as rapid an improvement as the best responses with other factor IX products for similar bleeds or procedures; good if the response was as satisfactory, with as much and as rapid an improvement as most responses with other factor IX products for similar bleeds or procedures; moderate if the response was less than satisfactory and not as good as most responses seen with other factor IX products when used for similar bleeding episodes or similar procedures; or no response if no improvement at all was observed.3
§ 29% (8/28) of patients (9 operative procedures) received postoperative BeneFIX by continuous infusion.3 BeneFIX is not licensed for use by continuous infusion – please refer to the BeneFIX Summary of Product Characteristics for further information.5
Speak to a member of the Pfizer haemophilia team.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020